Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Alnylam Pharmaceuticals 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE MA 02142 USA

www.alnylam.com Employees: 2,100 P: 617-551-8200 F: 617-551-8101

Description:

Alnylam Pharmaceuticals Inc. is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference. The company's pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas - genetic medicines, cardio-metabolic disease and hepatic infectious disease. The company's lead drug-Onpattro received regulatory approvals in the United States and Europe for the treatment of hereditary transthyretin-mediated amyloidosis in adults. The FDA approved Givlaari for acute hepatic porphyria. The FDA approved Oxlumo injection for subcutaneous use, for the treatment of primary hyperoxaluria type 1 to lower urinary oxalate levels in pediatric and adult patients. Moreover, the company is evaluating inclisiran for hypercholesterolemia in partnership with The Medicines Company acquired by Novartis. The FDA approved Leqvio to reduce low-density lipoprotein cholesterol with two doses a year..

Key Statistics

Overview:

Market Capitalization, $K 34,128,376
Enterprise Value, $K 33,315,686
Shares Outstanding, K 128,981
Annual Sales, $ 1,828 M
Annual Net Income, $ -440,240 K
Last Quarter Sales, $ 500,920 K
Last Quarter Net Income, $ -111,570 K
EBIT, $ -188,130 K
EBITDA, $ -91,100 K
60-Month Beta 0.39
% of Insider Shareholders 1.50%
% of Institutional Shareholders 92.97%
Float, K 127,046
% Float 98.50%
Short Volume Ratio 0.52

Growth:

1-Year Return 51.29%
3-Year Return 46.19%
5-Year Return 147.50%
5-Year Revenue Growth 2,340.65%
5-Year Earnings Growth 53.50%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.50 on 10/31/24
Next Earnings Date N/A
Earnings Per Share ttm -2.62
EPS Growth vs. Prev Qtr -569.23%
EPS Growth vs. Prev Year -175.65%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

ALNY Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -8.38%
Profit Margin % -24.08%
Debt/Equity 0.00
Price/Sales 18.97
Price/Cash Flow N/A
Price/Book 1,072.18
Book Value/Share 0.25
Interest Coverage -2.58
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar